2020
Obstructive sleep apnoe and cardiovascular, heart failure and mortality outcomes with empagliflozin versus placebo in the EMPA-REG OUTCOME trial
Yaggi H, Eliasson B, Kasai T, Marx N, Zinman B, Inzucchi S, Wanner C, Zwiener I, Wojeck B, Neeland I, Johansen O. Obstructive sleep apnoe and cardiovascular, heart failure and mortality outcomes with empagliflozin versus placebo in the EMPA-REG OUTCOME trial. European Heart Journal 2020, 41: ehaa946.2883. DOI: 10.1093/ehjci/ehaa946.2883.Peer-Reviewed Original ResearchEMPA-REG OUTCOMECardiovascular diseaseIncidence rateMajor adverse CV eventsPlacebo-controlled outcome trialsAdverse CV eventsGlomerular filtration rateSystolic blood pressureCox regression modelStandard of careType 2 diabetesCV deathCV eventsCV outcomesMultivariable adjustmentInhibitor empagliflozinOutcome trialsBlood pressureHeart failureWaist circumferenceMortality outcomesSodium glucoseFiltration rateMetabolic disturbancesPatients
2019
0494 Associations of Obstructive Sleep Apnea with Renal Function Decline in a Cohort of Veterans
Liu J, Qin L, McConaughey C, Yaggi H. 0494 Associations of Obstructive Sleep Apnea with Renal Function Decline in a Cohort of Veterans. Sleep 2019, 42: a198-a198. DOI: 10.1093/sleep/zsz067.492.Peer-Reviewed Original ResearchObstructive sleep apneaRenal function declineApnea-hypopnea indexChronic kidney diseaseSevere obstructive sleep apneaDiabetes statusFunction declineSleep apneaSleep medicine clinicHypertension statusAssociation of OSAMild-moderate obstructive sleep apneaSlower renal function declineClinic-based cohortCohort of patientsGlomerular filtration rateCommunity-based cohortCohort of veteransMultivariable regression analysisEnd of observationRenal functionBaseline prevalenceKidney diseaseMedicine clinicFiltration rate